| Name | PDZ1i |
|---|---|
| Synonyms |
N-(2,5-Dimethyl-4-(3-(5-phenyl-1,3,4-oxadiazol-2-yl)propanamido)phenyl)-8-oxo-5,6,7,8-tetrahydro-1H-cyclopenta[D][1,2,4]triazolo[1,5 -a]pyrimidine-2-cboxamide
113B7 1H-Cyclopenta[d][1,2,4]triazolo[1,5-a]pyrimidine-2-cboxamide, N-[2,5-dimethyl-4-[[1-oxo-3-(5-phenyl-1,3,4-oxadiazol-2-yl)propyl]amino]phenyl]-5,6,7,8-tetrahydro-8-oxo |
| Description | PDZ1i (113B7) is a specific inhibitor of MDA-9/Syntenin activity that inhibits MDA-9/Syntenin binding to EGFRvIII; selectively binds with micromolar affinity to the PDZ1 domain of MDA-9/Syntenin, with no affinity for PDZ2 domain of MDA-9/Syntenin; reduces invasion gains in GBM cells following radiation, inhibits crucial GBM signaling involving FAK and mutant EGFR, EGFRvIII, and abrogated gains in secreted proteases, MMP-2 and MMP-9, following radiation; results in smaller, less invasive tumors and enhanced survival in an in vivo glioma model. |
|---|---|
| References | References 1. Kegelman TP, et al. Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):370-375. View Related Products by Target Other Targets |
| Molecular Formula | C28H26N8O |
|---|---|
| Molecular Weight | 538.568 |